Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: TOK-001; Drug
Lead sponsor: LTN PHARMACEUTICALS, INC.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Bernardino, California • Baltimore, Maryland + 5 more

Conditions: Prostatic Neoplasms
Interventions: You Decide, Reducing Your Risks in the Crash; Other
Lead sponsor: University of North Carolina; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Greensboro, North Carolina

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: docetaxel 50mg/m2, docetaxel 75mg/m2; Drug
Lead sponsor: Peng Wang, MD PhD; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Urinary Incontinence, Prostate Cancer
Interventions: Prostatectomy, Surgisis Male Sling; Procedure · Device
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana • San Antonio, Texas

Conditions: Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions: AT-101, Bicalutamide, LHRH agent; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more

Conditions: Prostate Cancer
Interventions: Blood Drawing; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anemia, Fatigue, Prostate Cancer
Interventions: epoetin alfa, dexamethasone; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 140
States / cities: Modesto, California • Aurora, Colorado • Boulder, Colorado + 92 more

Conditions: Prostate Cancer, Diagnosis
Interventions: Software fusion prostate biopsy, Cognitive fusion prostate biopsy; Procedure
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Burlington, Massachusetts • Albany, New York • Hershey, Pennsylvania

Conditions: Cancer, Breast, Cancer, Colorectal, Cancer, Prostate
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 30 Years and older
Enrollment: 96,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Prostate Cancer
Interventions: Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 40
States / cities: Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more

Conditions: Prostate Cancer
Interventions: Questioners, blood specimens, prostate tissue specimens; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 35 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Apalutamide, Degarelix, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Drug · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions: NUV-1511; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more

Conditions: Prostate Cancer
Interventions: Nexrutine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: carbon-11 acetate PET scan; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Male only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Prostate Cancer, Bone Neoplasms
Interventions: AZD0530, Zoledronic Acid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Pleasant Hill, California • Sacramento, California • Middlebury, Connecticut + 6 more

Conditions: Prostatic Neoplasm
Interventions: Home-Based Exercise Program; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 40 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
Interventions: MR-guided Linac; Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Bridgeport, Connecticut • Derby, Connecticut • Greenwich, Connecticut + 3 more

Conditions: Prostate Cancer
Interventions: Low carbohydrate diet; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 20 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Localized Prostate Cancer
Interventions: CD-ROM-based prostate cancer treatment education, CD-ROM-based prostate ca treatment education+decision tools; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: Male only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Circulating Tumor Cells in Prostate Cancer Patients

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

Plant-based Diets and Risk of Cancer in the Adventist Health Study-2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Prostate Biomarker Study

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients

Positron Emission Tomography in Prostate Cancer

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer

Stereotactic Magnetic Resonance Guided Radiation Therapy

PSMA Imaging of Localized Prostate Cancer

DESTINY-PANTUMOUR04

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

Carbohydrate Restriction and Prostate Cancer Growth

Treatment Decision Making in Early-Stage Prostate Cancer